TEM: Tempus AI, Inc. Average Forecast Price

Corporate company logo of Tempus (TEM)

The Tempus AI, Inc (TEM) business relies on access to massive arrays of medical data and the development of high-precision therapy, while the current indicator stands at 89.42. Stringent FDA requirements and patient privacy laws create significant barriers to entry for new players. The market capitalization trend reflects growth driven by unique AI algorithms, which establish a powerful competitive advantage in genome analysis.

TEM Tempus: Analyst Consensus Forecast in the range 06/15/2024 - 11/11/2026
Manufactured products of Tempus AI

For Tempus AI, Inc (TEM), the consensus valuation serves as a filter for market noise, aggregating expert forecasts on the asset's fair value based on discounted cash flow analysis. This indicator reflects market confidence in the scalability of the DNA analysis IT platform, considering minimal environmental costs and server capacity efficiency as factors for long-term business sustainability.

Competing companies

Analyst Forecast Prices QGEN|Analyst Consensus Forecast IONS (Ionis)|Repligen Corp (RGEN) - Average Forecast Price|RNA - Price Target Chart|CRISPR (CRSP) - Consensus Target|WGS: Analyst Consensus Forecast|Broker Consensus Forecast RARE|Price Target Chart Beam Therapeutics|Broker Consensus Forecast SRPT (Sarepta Therapeutics)|Analyst Consensus Forecast TWST|Analyst Consensus Forecast 10x (TXG)|Intellia Therapeutics - Consensus Target|Analyst Forecast Prices STOK (stoketherapeutics.com)|BioLife Solutions - Analyst Consensus Forecast|Average Forecast Price Wave Life Sciences Ltd|Maze Tx (MAZE) - Price Target Chart|Consensus Target Sionna Corp|Price Target Chart Prime Medicine, Inc.|tayshagtx.com - Forecast Levels Chart|Consensus Target QURE (uniQure)|Analyst Consensus Forecast MeiraGTx Holdings (MGTX)|Price Target Chart Regenxbio RGNX|Analyst Median Target Solid Corp (SLDB)|OCGN: Consensus Target|Fair Value Consensus PACB (pacb.com)|BNTC: Analyst Consensus Forecast|Design Therapeutics Inc (DSGN) - Analyst Consensus Forecast|RCKT (Rocket Pharmaceuticals Inc) - Analyst Consensus Forecast|4D Molecular Corp (FDMT) - Analyst Median Target|Consensus Target LXEO (Lexeo Therapeutics)|KRRO (korrobio.com) - Fair Value Consensus|Analyst Consensus Forecast EDIT (Editas Medicine)|Analyst Median Target Silence Therapeutics PLC (SLN)|PRQR - Price Target Chart|CDXS (Codexis, Inc.) - Broker Consensus Forecast|SGMO: Analyst Consensus Forecast|Consensus Target Nautilus Bio|Consensus Target MGX|DTIL (Precision BioSciences Inc.) - Analyst Forecast Prices|Analyst Consensus Forecast GBIO|BOLD - Average Forecast Price|Price Target Chart Exicure XCUR|IMNN - Consensus Target|RXi Pharmaceuticals - Analyst Consensus Forecast|MBIO (Mustang Bio, Inc.) - Broker Consensus Forecast|transcodetherapeutics.com (RNAZ) - Price Target Chart|Broker Consensus Forecast BNGO|APDN (Applied DNA Sciences) - Analyst Consensus Forecast|Analyst Consensus Forecast bluebirdbio.com|Consensus Target IPA (ImmunoPrecise Antibodies)|Analyst Forecast Prices OMGA|Analyst Consensus Forecast OMIC (Singular Genomics Systems Inc)|Regulus (RGLS) - Average Forecast Price|SYRS - Price Target Chart|telesisbio.com (TBIO) - Consensus Target|TRACON Pharmaceuticals, Inc. (TCON) - Price Target Chart|Forecast Levels Chart UBX (Unity Biotechnology Inc.)